Use of highly-potent cannabis concentrate products: More common in U.S. states with recreational or medical cannabis laws.
Cannabis
Concentrates
Legalization
Marijuana
Potency
Vaping
Journal
Drug and alcohol dependence
ISSN: 1879-0046
Titre abrégé: Drug Alcohol Depend
Pays: Ireland
ID NLM: 7513587
Informations de publication
Date de publication:
01 12 2021
01 12 2021
Historique:
received:
30
08
2021
revised:
12
10
2021
accepted:
14
10
2021
pubmed:
30
11
2021
medline:
27
1
2022
entrez:
29
11
2021
Statut:
ppublish
Résumé
Highly-potent cannabis products, e.g., concentrates, entail greater risks of cannabis-related harms than lower-potency products such as plant or flower material. However, little information is available on whether individuals in U.S. states with recreational cannabis laws (RCL) or medical cannabis laws (MCL) are more likely than individuals in U.S. states without cannabis legalization (no-CL) to use highly-potent forms of cannabis. Cannabis-using adults in a 2017 online survey (N = 4064) provided information on state of residence and past-month cannabis use, including types of products used, categorized as low-potency (smoked or vaped plant cannabis) or high-potency (vaping or dabbing concentrates). Multivariable logistic regression models generated adjusted odds ratios (aOR) and 95% confidence intervals (CI) for use of high-potency cannabis products by state cannabis legalization status (RCL, MCL, no-CL). Compared to participants in no-CL states, participants in RCL states had greater odds of using high-potency concentrate products (aOR=2.61;CI=1.77-3.86), as did participants in MCL-only states (aOR=1.55;CI=1.21-1.97). When participants in RCL states and MCL states were directly compared, those in RCL states had greater odds of using high-potency concentrate products (aOR=1.69;CI=1.27-2.42). Although the sample was not nationally representative and the cross-sectional data precluded determining the direction of effect, results suggest that use of high-potency cannabis concentrates is more likely among those in RCL states. Clinicians in RCL states should screen cannabis users for harmful patterns of use. Policymakers in states that do not yet have RCL should consider these findings when drafting new cannabis laws, including the specific products permitted and how best to regulate them.
Sections du résumé
BACKGROUND
Highly-potent cannabis products, e.g., concentrates, entail greater risks of cannabis-related harms than lower-potency products such as plant or flower material. However, little information is available on whether individuals in U.S. states with recreational cannabis laws (RCL) or medical cannabis laws (MCL) are more likely than individuals in U.S. states without cannabis legalization (no-CL) to use highly-potent forms of cannabis.
METHODS
Cannabis-using adults in a 2017 online survey (N = 4064) provided information on state of residence and past-month cannabis use, including types of products used, categorized as low-potency (smoked or vaped plant cannabis) or high-potency (vaping or dabbing concentrates). Multivariable logistic regression models generated adjusted odds ratios (aOR) and 95% confidence intervals (CI) for use of high-potency cannabis products by state cannabis legalization status (RCL, MCL, no-CL).
RESULTS
Compared to participants in no-CL states, participants in RCL states had greater odds of using high-potency concentrate products (aOR=2.61;CI=1.77-3.86), as did participants in MCL-only states (aOR=1.55;CI=1.21-1.97). When participants in RCL states and MCL states were directly compared, those in RCL states had greater odds of using high-potency concentrate products (aOR=1.69;CI=1.27-2.42).
DISCUSSION
Although the sample was not nationally representative and the cross-sectional data precluded determining the direction of effect, results suggest that use of high-potency cannabis concentrates is more likely among those in RCL states. Clinicians in RCL states should screen cannabis users for harmful patterns of use. Policymakers in states that do not yet have RCL should consider these findings when drafting new cannabis laws, including the specific products permitted and how best to regulate them.
Identifiants
pubmed: 34844095
pii: S0376-8716(21)00654-2
doi: 10.1016/j.drugalcdep.2021.109159
pmc: PMC8667084
mid: NIHMS1759927
pii:
doi:
Substances chimiques
Hallucinogens
0
Medical Marijuana
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
109159Subventions
Organisme : NIDA NIH HHS
ID : P30 DA029926
Pays : United States
Organisme : NIDA NIH HHS
ID : T32 DA031099
Pays : United States
Organisme : NIDA NIH HHS
ID : T32 DA037202
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA048860
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA050032
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Références
Molecules. 2021 May 08;26(9):
pubmed: 34066753
Lancet. 2019 Oct 26;394(10208):1580-1590
pubmed: 31657733
J Health Econ. 2015 Jul;42:64-80
pubmed: 25863001
Lancet Psychiatry. 2017 Aug;4(8):643-648
pubmed: 28259650
World Psychiatry. 2020 Jun;19(2):179-186
pubmed: 32394566
Drug Alcohol Depend. 2016 Dec 01;169:26-32
pubmed: 27755989
JAMA Psychiatry. 2017 Jun 1;74(6):579-588
pubmed: 28445557
JAMA. 2017 Jan 10;317(2):207-209
pubmed: 27992619
JAMA Psychiatry. 2020 Oct 1;77(10):1044-1051
pubmed: 32459328
Psychol Med. 2015 Nov;45(15):3181-9
pubmed: 26213314
Addiction. 2017 Dec;112(12):2167-2177
pubmed: 28556310
Addiction. 2021 May;116(5):1000-1010
pubmed: 33160291
Int J Drug Policy. 2020 Feb;76:102658
pubmed: 31927413
Public Health Rep. 2021 Feb 26;:33354920988285
pubmed: 33636088
Drug Alcohol Depend. 2019 Feb 1;195:186-192
pubmed: 30573162
Addiction. 2014 Oct;109(10):1686-94
pubmed: 24894801
Biol Psychiatry Cogn Neurosci Neuroimaging. 2021 Jun;6(6):603-606
pubmed: 33508497
Front Psychiatry. 2020 Sep 23;11:591979
pubmed: 33173527
Front Psychiatry. 2021 May 28;12:643315
pubmed: 34122176
Lancet Psychiatry. 2016 Oct;3(10):954-964
pubmed: 27592339
J Clin Gastroenterol. 2018 Oct;52(9):778-783
pubmed: 29095419
Neuropharmacology. 2021 Aug 1;193:108610
pubmed: 34010617
Addiction. 2014 Jul;109(7):1101-9
pubmed: 24628797
Psychol Med. 2016 Mar;46(4):841-54
pubmed: 26610039
Lancet Psychiatry. 2015 Mar;2(3):233-8
pubmed: 26359901
Int J Drug Policy. 2016 Oct;36:141-7
pubmed: 26992484
Curr Opin Psychol. 2019 Dec;30:98-102
pubmed: 31071592
Ann Gastroenterol. 2020 Nov-Dec;33(6):571-578
pubmed: 33162734
Addiction. 2021 Jul;116(7):1782-1793
pubmed: 33217090
Drug Alcohol Depend. 2020 Apr 1;209:107900
pubmed: 32061947
Am J Drug Alcohol Abuse. 2019;45(6):698-706
pubmed: 30870053
Drug Alcohol Depend. 2017 Sep 1;178:399-407
pubmed: 28704769
Drug Alcohol Depend. 2020 Mar 1;208:107771
pubmed: 31952821
Am J Prev Med. 2020 Dec;59(6):873-879
pubmed: 33220757
J Forensic Sci. 2010 Sep;55(5):1209-17
pubmed: 20487147
Drug Alcohol Depend. 2021 Dec 1;229(Pt B):109137
pubmed: 34763137
JAMA Psychiatry. 2020 Feb 1;77(2):165-171
pubmed: 31722000
Biol Psychiatry. 2016 Apr 1;79(7):613-9
pubmed: 26903403
Addiction. 2020 Oct;115(10):1944-1953
pubmed: 32141142
Am J Public Health. 2020 Mar;110(3):363-369
pubmed: 31944840
Schizophr Res. 2018 Apr;194:4-12
pubmed: 28697856
Prev Sci. 2019 Feb;20(2):205-214
pubmed: 29103076
JMIR Public Health Surveill. 2018 May 02;4(2):e48
pubmed: 29720366
Prev Med. 2020 Feb;131:105956
pubmed: 31863787
Addict Behav. 2020 Oct;109:106479
pubmed: 32485547
Addict Behav. 2014 Oct;39(10):1430-3
pubmed: 24930049
Am J Psychiatry. 2016 Jun 1;173(6):588-99
pubmed: 26940807
Drug Alcohol Depend. 2017 Aug 1;177:299-306
pubmed: 28662974
Drug Alcohol Depend. 2018 Jun 1;187:155-159
pubmed: 29669296
Drug Alcohol Rev. 2021 Sep;40(6):900-913
pubmed: 33783029
Curr Opin Psychol. 2021 Apr;38:75-79
pubmed: 33839427
JAMA Psychiatry. 2015 Dec;72(12):1235-42
pubmed: 26502112
Drug Alcohol Rev. 2010 Nov;29(6):584-8
pubmed: 20973840